COSMOS Pharmaceutical Corporation
CSMYF · OTC
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Revenue | $1,852,007 | $259,122,000 | $246,332,000 | $244,095,000 |
| % Growth | -99.3% | 5.2% | 0.9% | – |
| Cost of Goods Sold | $1,463,274 | $205,049,000 | $193,198,000 | $192,584,000 |
| Gross Profit | $388,733 | $54,073,000 | $53,134,000 | $51,511,000 |
| % Margin | 21% | 20.9% | 21.6% | 21.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $107,000 | $0 | $0 |
| SG&A Expenses | $309,552 | $24,506,000 | $42,194,000 | $42,635,000 |
| Sales & Mktg Exp. | $0 | $1,561,000 | $0 | $0 |
| Other Operating Expenses | $0 | $20,791,000 | -$343,000 | $112,000 |
| Operating Expenses | $309,552 | $45,297,000 | $41,851,000 | $42,747,000 |
| Operating Income | $79,181 | $8,776,000 | $11,283,000 | $8,764,000 |
| % Margin | 4.3% | 3.4% | 4.6% | 3.6% |
| Other Income/Exp. Net | $3,005 | $410,000 | $460,000 | $613,000 |
| Pre-Tax Income | $82,186 | $9,186,000 | $11,743,000 | $9,377,000 |
| Tax Expense | $26,625 | $551,000 | $3,828,000 | $3,092,000 |
| Net Income | $55,555 | $8,635,000 | $7,915,000 | $6,285,000 |
| % Margin | 3% | 3.3% | 3.2% | 2.6% |
| EPS | 0.7 | 108.95 | 99.86 | 79.3 |
| % Growth | -99.4% | 9.1% | 25.9% | – |
| EPS Diluted | 0.7 | 108.95 | 99.86 | 79.3 |
| Weighted Avg Shares Out | 79,257 | 79,257 | 79,257 | 79,257 |
| Weighted Avg Shares Out Dil | 79,257 | 79,257 | 79,257 | 79,257 |
| Supplemental Information | – | – | – | – |
| Interest Income | $184 | $12,000 | $0 | $0 |
| Interest Expense | $748 | $109,000 | $34,000 | $37,000 |
| Depreciation & Amortization | $39,081 | $6,013,000 | $4,981,000 | $5,293,000 |
| EBITDA | $122,022 | $15,306,000 | $15,921,000 | $14,169,000 |
| % Margin | 6.6% | 5.9% | 6.5% | 5.8% |